Our immune gene signatures associated with prolonged PFS on TT are in accordance with Wongchenko et al. ́s gene expressing profiling of 223 BRAF mutated melanoma tumors from patients treated with BRAFi (vemurafenib) alone in two clinical trials (BRIM-2 and BRIM-3) where an immune signature significantly correlated with a longer PFS [28]. The gene discussed is BRAF; the disease is melanoma.